Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT ID: NCT05653765
Last Updated: 2025-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
2663 participants
OBSERVATIONAL
2022-12-20
2025-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To determine the value of AMR in predicting the long-term clinical prognosis of patients with STEMI after PPCI, and to find the best cut-off value.
* Analyze the factors of PPCI affecting AMR and explore the effective measures of PPCI microcirculation protection.
Radiographic images of STEMI receiving primary PCI treatment in several chest pain centers in China will be included. The last image of the infarct-related vessel will be used as a target to calculate its AMR. The relationship between AMR and long-term clinical prognosis was analyzed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimized Cardioprotection Therapy in Obese Subjects With AMI
NCT04570514
Circulating PRCP in STEMI Patients Undergoing Primary PCI
NCT02772133
Intramyocardial Haemorrhage in Patients With Primary STEMI
NCT03677466
The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.
NCT02131103
Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction
NCT07181356
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
diagnostic cohort/derivation cohort
The diagnostic/derivation cohort included STEMI patients who underwent PCI within 12 hours and CMR. The optimal AMR cutoff value for diagnosing CMD using CMR was determined by analyzing ROC curves.
No interventions assigned to this group
prognostic cohort/validation cohort
The prognostic cohort enrolled STEMI patients who underwent PPCI within 12 hours. All patients were followed up for at least 1 year.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 1 myocardial infarction
* Receive PPCI
Exclusion Criteria
* Structural heart disease with moderate to severe aortic valve or mitral regurgitation and or stenosis that may affect cardiac function
* Dialysis patients with severe renal insufficiency
* Severe and uncontrollable arrhythmia
* Complicated with dilated cardiomyopathy
* Unable to tolerate dual antiplatelet therapy
* Severe and uncontrollable anemia
* Hyperthyroidism
* TIMI blood flow 0-1 grade after PPCI
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henan Institute of Cardiovascular Epidemiology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Muwei Li, MD
Role: STUDY_CHAIR
Fuwai central China cardiovascular hospotial
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shangqiu first people's Hospital
Shangqiu, Henan, China
Department of Cardiology, First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Yongcheng Central Hospital
Yongcheng, Henan, China
Fuwai central China cardiovascular Hospital
Zhengzhou, Henan, China
Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HenanICE202201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.